医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

SpinalCyte, LLC Receives New Chinese Patent for Spinal Disc Tissue Engineering

2016年01月08日 PM11:12
このエントリーをはてなブックマークに追加


 

HOUSTON

SpinalCyte, LLC, a Texas-based tissue engineering technology company focused on regrowth of the spinal disc nucleus using human dermal fibroblasts, announced today the issuance of Chinese Patent No. ZL 201110261353.3, “Method Of Differentiating Human Dermal Fibroblasts Into Chondrocyte-Like Cells Using Mechanical Strain.” The technology described in the patent involves incoporating a three dimensional matrix to expose the fibroblasts to a mechanical strain using intermittent hydrostatic pressure and/or fluid shear stress. Other claims provide for exposing the cells to hypoxia, growth factors and ascorbic acid.

“The issuance of this patent is a major step forward in our international validation for the SpinalCyte technology. This is a significant milestone for us and we are pleased the Chinese Patent Office has validated the uniqueness of our technology which includes 10 U.S. and foreign patents issued and directly owned by the company, along with 34 patents pending,” said Pete O’Heeron, Chief Executive Officer for SpinalCyte. “We feel the future for spinal disc regeneration will be a cell based therapy solution and we continue to build our intellectual property to protect our leading position in this field.”

About SpinalCyte, LLC

Based in Houston, Texas, SpinalCyte, LLC is a tissue engineering technology company founded for the purpose of developing an innovative and autologous solution for spinal nucleus replacement using human dermal fibroblasts. The goal of SpinalCyte is to develop a cartilage regeneration technology using autologous dermal cells harvested from the patient. To date, SpinalCyte has been funded entirely by angel investors.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160108005145/en/

CONTACT

SpinalCyte, LLC
Pete O’Heeron, 281-461-6211
CEO
pete@spinalcyte.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • フェリングが微生物叢ベースのライブバイオ治療薬RBX2660に関する米国FDA諮問委員会会議の開催を発表
  • 辉凌宣布美国FDA咨询委员会就公司基于微生物群的在研活体生物疗法RBX2660召开会议
  • Taiwan Excellence Pavilion Showcasing at The AACC Expo (American Association for Clinical Chemistry) for the First Time
  • Cellworks Singula™ TRI Provides Superior OS Predictions for NSCLC Patients Beyond NCCN-Guideline Genomic Factors
  • 2022 International Symposium on Human Identification (ISHI) Keynote DeNeen L. Brown Outlines Search for Victims of 1921 Tulsa Race Massacre